The U.K.'s VASTox has simultaneously acquired DanioLabs and Dextra Laboratories for a collective £16.5 million. The deal gives VASTox two clinical and two pre-clinical programs in neurological and ophthalmic diseases. VASTox also touted its acquisition of new expertise in zebrafish chemical genomics and carbohydrate chemistry through the acquisition of two laboratories in Cambridge and Reading. DanioLabs claimed the bulk of the money, with a price of £15 million.
- see the release for more information (.pdf)